Precision Diagnostics Market Report 2026

The precision diagnostics market size has grown rapidly in recent years. It will grow from $110.94 billion in 2025 to $126.86 billion in 2026 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to advancements in genomic research technologies, increasing prevalence of chronic diseases, growing use of biomarker-based testing, expansion of diagnostic laboratory infrastructure, rising adoption of personalized medicine.

The precision diagnostics market size is expected to see rapid growth in the next few years. It will grow to $220.51 billion in 2030 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to increasing demand for individualized treatment planning, rising investments in genomic diagnostics, expansion of liquid biopsy applications, growing integration of ai-driven diagnostics, increasing focus on preventive healthcare. Major trends in the forecast period include increasing adoption of genetic and molecular testing, rising use of companion diagnostics, growing integration of ai in diagnostic interpretation, expansion of precision oncology applications, enhanced focus on early disease detection.

The increasing prevalence of chronic diseases is expected to drive the growth of the precision diagnostics market in the coming years. Chronic diseases are conditions that persist for three months or longer and often worsen over time. Precision diagnostics support patients with chronic conditions such as cancer and cardiovascular diseases by enabling accurate disease identification and supporting personalized healthcare management through precise diagnostic results. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of individuals aged 50 years and older in the United States with at least one chronic condition is projected to reach 142.66 million by 2050. Therefore, the rising burden of chronic diseases is contributing to the growth of the precision diagnostics market.

Major companies operating in the precision diagnostics market are emphasizing innovation through the introduction of advanced solutions, such as AI-driven video analysis tools, to improve patient engagement and enhance comprehension of complex medical information, ultimately enabling individuals to better manage their health. AI-driven video analysis tools utilize artificial intelligence to process and interpret video content, simplifying complex data such as health reports by highlighting key parameters and delivering clear insights that support informed decision-making. For instance, in August 2024, Healthians, an India-based diagnostic company, launched an industry-first AI-driven video analysis tool designed to simplify medical data by emphasizing key health indicators and explaining their relevance, thereby guiding users through their health reports. This feature allows users to receive personalized insights within 15 to 30 minutes after completing a short questionnaire on the Healthians app, improving their ability to make informed healthcare decisions.

In February 2024, Myriad Genetics, a US-based molecular diagnostics company, acquired select assets from Intermountain Precision Genomics for an undisclosed amount. Through this acquisition, Myriad Genetics aims to strengthen its tumor profiling capabilities and broaden its precision oncology testing portfolio, including advanced genomic analyses for solid tumors and liquid biopsies. Intermountain Precision Genomics is a US-based laboratory specializing in DNA- and RNA-based tumor testing and provides CLIA-certified genomic profiling solutions for both clinical and research applications in oncology.

Major companies operating in the precision diagnostics market are F Hoffmann La Roche Ltd, Abbott Laboratories, Danaher Corporation, Becton Dickinson And Company, Thermo Fisher Scientific Inc, Quest Diagnostics Inc, Siemens Healthineers AG, Agilent Technologies Inc, PerkinElmer Inc, Beckman Coulter Inc, Charles River Laboratories International Inc, Sysmex America Inc, Waters Corporation, Bio Rad Laboratories Inc, Bruker Corporation, Qiagen NV, Bio Techne Corporation, Illumina Inc, Luminex Corporation, BioFire Diagnostics LLC, Genomic Health Inc, Guardant Health Inc, Natera Inc, Exact Sciences Corporation.

North America was the largest region in the precision diagnostics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the precision diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the precision diagnostics market by increasing costs of imported sequencing instruments, reagents, laboratory equipment, and advanced diagnostic consumables. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported high-end technologies, while Asia-Pacific faces cost pressures in equipment manufacturing and export. These tariffs raise testing costs and can slow adoption of advanced diagnostics. However, they also encourage domestic production of diagnostic tools, regional manufacturing of reagents, and increased investment in local precision diagnostics innovation.

The precision diagnostics market research report is one of a series of new reports that provides precision diagnostics market statistics, including precision diagnostics industry global market size, regional shares, competitors with a precision diagnostics market share, detailed precision diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the precision diagnostics industry. This precision diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Precision diagnostics is a specialized area of precision medicine that delivers healthcare by utilizing individual-specific data, including genetic, environmental, and lifestyle information, to improve disease prevention, diagnosis, and treatment. It is used to generate detailed genetic insights into a patient’s clinical background, which can support studies and decision-making throughout the treatment process.

The primary categories of precision diagnostics include genetic tests, esoteric tests, and others. Genetic tests are laboratory analyses conducted to identify variations in an individual’s DNA, such as changes in chromosomes, genes, or gene expression within cells or tissues. The technologies involved include next-generation sequencing (NGS), polymerase chain reaction (PCR), in situ hybridization (ISH), mass spectrometry, immunohistochemistry (IHC), and others. These diagnostics are applied across multiple areas including oncology, infectious diseases, cardiovascular conditions, neurology, genetic disorders, and others, and are utilized by hospitals and clinics, diagnostic laboratories, research institutes, pharmaceutical and biotechnology companies, and others.

The precision diagnostics market consists of revenues earned by entities by providing precision imaging, molecular imaging, on-device X-ray AI algorithms, and automated MR workflow. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision diagnostics market also includes sales of medical diagnostic kits, rapid test kits, instruments and analyzers, and diagnostic equipment that are used in precision diagnostics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.